20-F/A 1 y55052e20vfza.htm AMENDMENT NO. 1 TO FORM 20-F 20-F/A
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F/A
(Amendment No. 1)
     
o   REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
Or
     
þ   ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended March 31, 2006
Or
     
o   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to _________
Commission File Number: 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Exact name of Registrant as specified in its charter)
     
Not Applicable
(Translation of Registrant’s name
into English) 		  ANDHRA PRADESH, INDIA
(Jurisdiction of incorporation or
organization)
7-1-27, Ameerpet
Hyderabad, Andhra Pradesh 500 016, India
+91-40-23731946
(Address of principal executive offices)
Securities registered or to be registered pursuant to Section 12(b) of the Act.
     
Title of Each Class   Name of Each Exchange on which Registered
 
    
American depositary shares, each representing one equity share
  New York Stock Exchange
 
    
Equity Shares*
  New York Stock Exchange
 
*   Not for trading, but only in connection with the registration of American depositary shares, pursuant to the requirements of the Securities and Exchange Commission.
Securities registered or to be registered pursuant to Section 12(g) of the Act. None.
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. None.
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.
76,694,570 Equity Shares
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes    þ    No    o
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Yes    o    No    þ
Note — Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes    þ    No    o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Securities Exchange Act of 1934. (Check one):
Large accelerated filer    þ      Accelerated filer    o      Non-accelerated filer
Indicate by check mark which financial statement item the registrant has elected to follow.
Item 17      o      Item 18      þ
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).
Yes      o    No      þ
 
 

 

TABLE OF CONTENTS

SIGNATURES
EXHIBIT INDEX
EX-4.3: SALE AND PURCHASE AGREEMENT
EX-99.1: CERTIFICATION
EX-99.2: CERTIFICATION

Table of Contents

EXPLANATORY NOTE
In our Annual Report on Form 20-F for the year ended March 31, 2006, we filed as Exhibit 4.3 a “Sale and Purchase Agreement Regarding the Entire Share Capital of Beta Holding GmbH dated February 15th/16th 2006,” portions of which were redacted and filed separately with the SEC pursuant to a request for confidential treatment.
The purpose of this amendment is solely to replace said agreement with a new version where certain of the information previously redacted (primarily consisting of business addresses and registration numbers) is now included without redaction. Certain other portions of this new version of the agreement will continue to be redacted and filed separately with the SEC pursuant to a request for confidential treatment
This amendment to our Annual Report on Form 20-F does not otherwise update the information set forth in the original filing of the Annual Report on Form 20-F.

 

Table of Contents

SIGNATURES
The registrant hereby certifies that it meets all of the requirements for filing on Form 20—F/A and that it has duly caused and authorized the undersigned to sign this Amendment No. 1 to Annual Report on its behalf.
         
  DR. REDDY’S LABORATORIES LIMITED
 		  
  By:   /s/ G.V. Prasad    
    G.V. Prasad   
    Executive Vice Chairman & CEO   
 
     
  By:   /s/ Saumen Chakraborty    
    Saumen Chakraborty   
    Chief Financial Officer   
 
Hyderabad, India
April 21, 2008

 

Table of Contents

EXHIBIT INDEX
     
Exhibit Number   Description of Exhibits
 
    
4.3****
  Sale and Purchase Agreement Regarding the Entire Share Capital of Beta Holding GmbH dated February 15th/16th 2006.
99.1
  Certification of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
99.2
  Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
****   Portions of exhibit have been omitted and filed separately with the SEC pursuant to a request for confidential treatment.